Effect of autologous platelet-rich plasma for treatment of recurrent pregnancy loss: a randomized controlled trial
- Author:
Leila NAZARI
1
;
Saghar SALEHPOUR
;
Sedighe HOSSEINI
;
Teibeh HASHEMI
;
Nasrin BORUMANDNIA
;
Elham AZIZI
Author Information
- Publication Type:Original Article
- From:Obstetrics & Gynecology Science 2022;65(3):266-272
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:Recurrent pregnancy loss (RPL) is a fertility problem for which no exact mechanism of abortion or efficient treatment has been described. This study was conducted between 2018 and 2019 to investigate the effectiveness of autologous platelet-rich plasma (PRP) in improving the live birth rate of women with RPL who required in vitro fertilization (IVF).
Methods:A total of 63 patients with at least two previous pregnancy losses and no specific cause detected for the RPL were included and randomly assigned into two groups (PRP and control). Intrauterine infusion of 0.5 mL of autologous PRP was performed 48 hours before embryo transfer in the PRP group. Women in the control group received standard treatment.
Results:Forty patients completed the study. The baseline and cycle characteristics of the participants did not differ significantly between the PRP and control groups. The clinical pregnancy rate was higher in the PRP group (35% vs. 20%, P=0.288). The live birth rate was 15% in the PRP group, but no live births were recorded in the control group (P=0.231).
Conclusion:This is the first study to show that intrauterine infusion of PRP in patients with RPL who undergo IVF may increase the chance of live birth.
